lancet semaglutide Semaglutide - STEP UP T2D semaglutide benefits both patients with HFpEF and those with HFrEF Exploring the Latest Advancements in Semaglutide Research: A Deep Dive from The Lancet

LancetWegovy The field of metabolic and cardiovascular health is rapidly evolving, with ongoing research shedding new light on the efficacy and applications of semaglutide作者：J Deanfield·2025·被引用次数：26—The SELECT trial foundsemaglutidereduced major adverse cardiovascular events (MACE) in patients with overweight or obesity with .... Presented in leading medical journals like The Lancet, a growing body of evidence highlights the multifaceted benefits of this glucagon-like peptide-1 (GLP-1) analogue, particularly for individuals managing conditions such as type 2 diabetes and obesity. This article delves into the most recent findings, exploring its impact on weight management, cardiovascular outcomes, and heart failure, while also considering emerging treatment alternatives.

Semaglutide: Proven Efficacy in Weight Management and Diabetes Control

Semaglutide has established itself as a significant therapeutic agent, with its 7.2 mg and 2.4 mg formulations demonstrating considerable success. The once-weekly semaglutide 2.4 mg dose, in particular, is approved for weight management in adults with obesity or overweight, especially when co-occurring with at least one obesity-related comorbidity. Studies conducted in diverse populations, including Asian adults, have reaffirmed its effectiveness. For instance, research presented in The Lancet has shown that once-weekly semaglutide 2.4 mg in an Asian population with a BMI of 25 kg/m² or higher leads to clinically meaningful reductions in body weight16小时前—The Lancet: New weight loss pill leads togreater blood sugar control and weight lossfor people with diabetes than current oral GLP-1, .... This is particularly relevant as obesity is defined differently in many Asian populations due to increased health risks at lower BMI thresholds, consistent with WHO recommendations. This semaglutide medication has demonstrated its capability to offer an easier and more reliable way to lose weight and combat the health impacts associated with obesity.

Beyond weight loss, semaglutide plays a crucial role in glycemic control. For individuals with type 2 diabetes, it offers greater blood sugar control and weight lossLilly's oral GLP-1, orforglipron, delivered superior blood .... Clinical trials consistently show that semaglutide reduces blood sugar levels and body weight, making it a vital tool in managing this complex conditionThe Lancet: New weight loss pill leads to greater blood .... The once-daily oral formulation, when compared to other oral GLP-1 drugs, has also shown promise.Semaglutide: weighing up the benefits and risks While semaglutide—the only available oral GLP-1 drug currently—has specific administration requirements like being taken on an empty stomach, its efficacy in improving A1C levels remains a key benefit.

Cardiovascular Benefits: The SELECT Trial and Beyond

A significant area of advancement for semaglutide lies in its cardiovascular benefits. The landmark SELECT trial, extensively discussed in The Lancet, has provided compelling evidence that semaglutide reduced major adverse cardiovascular events (MACE) in patients with overweight or obesity作者：J Deanfield·2025·被引用次数：26—The SELECT trial foundsemaglutidereduced major adverse cardiovascular events (MACE) in patients with overweight or obesity with .... This finding is particularly impactful for individuals at high cardiovascular risk. Furthermore, new perspectives on semaglutide in cardiovascular disease suggest its potential to mitigate risks, with studies examining its impact by baseline characteristics of patients. The findings from the SELECT trial are a testament to the broader benefits of sustained weight loss and improved metabolic health facilitated by semaglutide1天前—A new trial found that Eli Lilly's GLP-1 pill resulted ingreater reductions in blood sugar levels and weightthan oral semaglutide did, ....

Impact on Heart Failure: A New Frontier

The positive effects of semaglutide extend to cardiovascular health beyond MACE, specifically in the context of heart failure1天前—The use of the drug orforglipronreduces blood sugar levels and body weightmore than semaglutide, the other available oral treatment.. Research indicates that semaglutide benefits both patients with HFpEF and those with HFrEF, demonstrating efficacy without significant heterogeneity in outcomes. This is a crucial development, as semaglutide—a new treatment for obesity-related heart failure with preserved ejection fraction—offers hope for improved quality of life and reduced exacerbations for a patient population with significant unmet needs. Studies have explored its effects on walking capacity, symptoms, and overall quality of life, suggesting a comprehensive improvement in function for individuals with obesity-related heart failure.

Emerging Alternatives and Comparative Efficacy

While semaglutide continues to be a cornerstone therapy, the medical landscape is dynamic. Emerging treatments, such as Eli Lilly's oral GLP-1, orforglipron, are showing promising results in head-to-head comparisons作者：I Lingvay·2025·被引用次数：20—Semaglutide2·4 mg is approved for weight management in adults with obesity or overweight in the presence of at least one obesity-related .... Recent findings presented in The Lancet Diabetes & Endocrinology suggest that orforglipron delivered superior blood sugar control and weight loss compared to oral semaglutide in type 2 diabetes patients. This new non-peptide oral GLP-1 agonist, orforglipron, can be taken once daily without fasting or fluid-intake restrictions, potentially addressing some of the administration challenges associated with current oral semaglutide.1天前—Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oralsemaglutidein head-to-head type 2 ... This signifies a step forward in oral GLP-1 therapies, offering patients more convenient and potentially more effective options.Semaglutide and cardiovascular outcomes by baseline ... The trial results indicate that orforglipron is more effective than semaglutide in reducing blood sugar levels and body weight1天前—This study aimed to compare the efficacy and safety of orforglipron with oralsemaglutidein individuals with type 2 diabetes inadequately ....

Future Directions and Considerations

The research landscape for semaglutide and related GLP-1 agonists is continuously expanding.1天前—This study aimed to compare the efficacy and safety of orforglipron with oralsemaglutidein individuals with type 2 diabetes inadequately ... The STEP UP trial and STEP UP T2D trial groups are presenting new findings on efficacy and safety, further refining our understanding of these treatments. While the benefits are substantial, ongoing investigations also consider factors such as cost and accessibility.1天前—Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oralsemaglutidein head-to-head type 2 ... Studies examining the association between income and prescriptions for semaglutide for weight loss highlight the importance of addressing economic barriers to ensure equitable access to these life-changing medications. As evidence mounts, the role of semaglutide and GLP-1 drugs combined with healthy lifestyle habits in reducing cardiovascular risk among diabetes patients is becoming increasingly clear, emphasizing a holistic approach to patient care.作者：J Butler·2024·被引用次数：312—Semaglutide—a new treatment for obesity-related heart failurewith preserved ejection fraction? Donal et al. The LancetApril 7, 2024.

In conclusion, the latest research featured in The Lancet and other esteemed publications underscores the transformative impact of semaglutide on managing chronic conditions like type 2 diabetes and obesity2天前—GLP-1 drugs combined with healthy lifestyle habits linked with reduced cardiovascular risk among diabetes patients. By. Maya Brownstein.. Its proven benefits in weight management, cardiovascular risk reduction, and heart failure treatment, coupled with the emergence of new therapeutic options, paint a promising picture for the future of metabolic and cardiovascular healthcare. The ongoing evolution of these potent medications, including the continued exploration of semaglutide 2.作者：J Moody·2024—Semaglutide could offer an easier and more reliable way to lose weightand combat the health impacts people with obesity face.4 mg taken once per week and its various applications, promises to further enhance patient outcomes and improve quality of life.